Managers / Q2 2022 · view latest →
Qiming U.S. Ventures Management, LLC
CIK 0001909617 · 11100 NE 8TH ST., SUITE 200, BELLEVUE, WA, 98004 · (425) 709-0772
Summary
Qiming U.S. Ventures Management, LLC reported $72M in U.S.-listed holdings across 7 positions for Q2 2022.
The portfolio is heavily concentrated: Icosavax alone accounts for 27.9% of reported value.
Compared with Q1 2022, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 84.5% · $61M
- Common Stock · 15.5% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| HILLEVAX INC | NEW | +558.9K | 558.9K | +$6M | $6M |
| TALARIS THERAPEUTICS INC | HELD | +0 | 2.93M | −$16M | $13M |
| JASPER THERAPEUTICS INC | HELD | +0 | 5.85M | −$9M | $11M |
| KEZAR LIFE SCIENCES INC | HELD | +0 | 828.7K | −$7M | $7M |
| ICOSAVAX INC | HELD | +0 | 3.51M | −$5M | $20M |
| ELEVATION ONCOLOGY INC | HELD | +0 | 2.37M | −$3M | $3M |
| VENTYX BIOSCIENCES INC | HELD | +0 | 910.3K | −$1M | $11M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ICOSAVAX INC | COM | 27.92% | $20M | 3.51M |
| 2 | TALARIS THERAPEUTICS INC | COM | 18.36% | $13M | 2.93M |
| 3 | JASPER THERAPEUTICS INC | COM | 15.68% | $11M | 5.85M |
| 4 | VENTYX BIOSCIENCES INC | COM | 15.45% | $11M | 910.3K |
| 5 | KEZAR LIFE SCIENCES INC | COM | 9.51% | $7M | 828.7K |
| 6 | HILLEVAX INC | COM | 8.48% | $6M | 558.9K |
| 7 | ELEVATION ONCOLOGY INC | COM | 4.61% | $3M | 2.37M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $56M | 4 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $24M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $23M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $51M | 6 | Jan 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $51M | 6 | Nov 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $53M | 6 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $90M | 6 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $109M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $75M | 7 | Nov 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $95M | 7 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $83M | 7 | Apr 25, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $76M | 7 | Jan 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $69M | 7 | Nov 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $72M | 7 | Jul 22, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $106M | 6 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $217M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.